Lightnews — Scholar-powered news

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 7h

✨ Day 2 at #ESMO2025 was all about exciting conversations and great energy.

We’re thrilled to meet so many oncology professionals — join us again on Day 3! 🤝

#ONCOnews #OncoAlert #OncEd #myESMOStory #OncTwitter #ESMO25 #Berlin #Germany

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 10h

#ONCOnews #OncoAlert #OncEd#NSCLC #LungCancer #Oncology #ClinicalTrials #ESMO2025

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 10h

✨#ESMO25✨

🚨BREAKING: Zongertinib in Advanced HER2-Mutant NSCLC

🎯 Boehringer’s zongertinib showed a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC in the Phase Ib Beamion LUNG-1 trial at #ESMO25.

🔗 Read more: bit.ly/ONCOnews18O-4

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 11h

✨#ESMO25✨

🚨BREAKING: AMPLITUDE Trial Updates!

📊 Patient-reported outcomes from the AMPLITUDE trial evaluating Niraparib + Abiraterone Acetate + Prednisone in metastatic hormone-sensitive prostate cancer (mHSPC) patients with homologous recombination repair (HRR) mutations.

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 13h

#ONCOnews #OncoAlert #OncEd #OvarianCancer #CancerResearch #ClinicalTrials #ESMO2025

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 13h

✨#ESMO25✨

🚨BREAKING: Sevabertinib in Advanced HER2-Mutant NSCLC.

➡️ HER2 mutations occur in 2–4% of NSCLC patients.

💊 Sevabertinib, an oral reversible tyrosine kinase inhibitor, shows promising anti-HER2 activity in preclinical models.

🔗 Read more: bit.ly/ONCOnews18O-2

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 14h

#ONCOnews #OncoAlert #OncEd #LungCancer #Phase3Data #OncologyNews #ESMO2025

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 14h

✨#ESMO25✨

🚨BREAKING: Phase 3 Data!

📈 Osimertinib + chemotherapy significantly improved overall survival vs. Osimertinib alone in patients with EGFR-mutated advanced NSCLC.

✅ Reinforces its potential as a new first-line standard of care.

🔗 Read more: bit.ly/ONCOnews18O-1

1 1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

✨#ESMO25✨

🚨BREAKING: POTOMAC Phase 3 Update!
➡️ 32% lower risk of disease recurrence or death in high-risk non–muscle-invasive bladder cancer with Imfinzi(durvalumab) vs. BCG alone.
⏱️ 1year of Imfinzi added to BCG induction and maintenance delivered early and sustained disease-free survival benefit.

1 1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

✨Inspiring conversations & new connections at #ESMO25! A big thank you to everyone who visited our booth.

Excited for more learning, networking, and innovation on Day 2!

#ONCOassist #OncoAlert #myESMOStory #ESMO2025 #OncologyUpdates #MedicalConference #Berlin #Germany #OncTwitter

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

Test Banner

bit.ly

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

✨#ESMO25✨

🚨BREAKING: 5-Year NATALEE Data!

✅ Kisqali® (ribociclib) + endocrine therapy shows 28% reduction in recurrence risk in the broadest HR+/HER2- early breast cancer population.

💊 Demonstrates 29.1% risk reduction in distant disease-free survival with no new safety signals post-treatment.

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

💊 It’s the first immune checkpoint inhibitor-based regimen in this setting to demonstrate OS benefit vs. placebo + chemotherapy (± bevacizumab).

🔗 Read more: bit.ly/ONCOnews17O-1

#ONCOnews #OncoAlert #OncEd #OvarianCancer #OncologyResearch #CancerTreatment #ESMO2025

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

✨#ESMO25✨

🚨BREAKING: Phase 3 KEYNOTE-B96 Trial Results!

✅ Merck’s KEYNOTE-B96 met its secondary endpoint — showing a statistically significant improvement in OS in platinum-resistant recurrent ovarian cancer.

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 2d

📢 BREAKING: Phase III REACH2 Trial!

➡️ Final Analysis: Evaluates efficacy and safety of Ruxolitinib versus best available therapy in steroid-refractory acute graft-versus-host disease.

🔬 Phase III Results: Provides insights into treatment outcomes and potential advantages over standard therapy.

1 1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 2d

#ONCOassist #OncoAlert #ESMO25 #Oncology #MedTech #myESMOStory #ESMO2025 #OncTwitter

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 2d

✨Meet the ONCOassist Team at #ESMO2025!

We’re thrilled to announce that Eoin O'Carroll, Kevin Bambury, Dr. Suleka A.R., and Lavi Malhotra will be representing ONCOassist at #ESMO2025! 🎉

🤝 Catch up with the team at Booth 2050.

Be sure to stop by and say hello!

1 1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 3d

🚨BREAKING: TUKYSA® (tucatinib) combination significantly improves PFS as first-line maintenance in HER2+ metastatic breast cancer in the Phase 3 HER2CLIMB-05 trial.

✅ Met primary endpoint with statistically significant and meaningful PFS improvement vs placebo, with a tolerable safety profile.

1 1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 4d

Download the ONCOassist app:
📥 iOS: apple.co/4iuMxfS
📥 Android: bit.ly/oncoassiston...
📥Webapp: bit.ly/ONCOassistOn...

‎ONCOassist

‎Please note: This application, as a decision-support aid, is to be used by a practicing healthcare professional(“HCP”) and does not replace clinical judgement. It is not designed for use by…

apple.co

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 4d

🎥 New on #OncologyBytes

"One-size-fits-all doesn't work in cancer care."

Dr. Yüksel Ürün at #IUCS2025 discusses biomarkers, access & personalisation in urologic oncology.

📺 Watch: youtu.be/FouL6neFxX8

#ONCOassist #PrecisionOncology #CancerCare #Oncoassist #Oncoalert

1 1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 4d

🚨BREAKING: The Phase III PACIFIC-2 study explores concurrent durvalumab with platinum-based chemoradiotherapy in unresectable Stage III NSCLC

🔹 Immunotherapy targeting PD-L1 has improved outcomes when given after cCRT.

🔗 bit.ly/ONCOnews14O-1

#ONCOnews #OncoAlert #OncEd #LungCancer #NSCLC

1